Paterna BioSciences has filed a notice of an exempt offering of securities to raise $9,949,122.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Paterna BioSciences is raising up to $9,949,122.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Edward Rowland played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Paterna BioSciences
Solving Male Infertility & Optimizing Offspring Health with In Vitro Spermatogenesis – A New Paradigm in Human Reproduction. After more than a decade of collaboration among the founders, Paterna has deciphered the in vivo environment for spermatogenesis and are applying it to in vitro spermatogenesis, facilitating the treatment of male infertility. We started Paterna because our founders wanted to ensure that all couples could have healthy children. We focus on male fertility and are developing in vitro spermatogenesis from stem cells to mature, healthy sperm, enabling IVF and achieving life- and world-changing results. Of the ~3 million IVF cycles annually around the world, ~50% of these fail and a male factor causes ~50% of these failures.
To learn more about Paterna BioSciences, visit http://paternabio.com/
Contact:
Edward Rowland, Chief Executive Officer
973-462-9695
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.